Prime Medicine (PRME) Depreciation & Amortization (CF) (2021 - 2026)

Prime Medicine has reported Depreciation & Amortization (CF) for 6 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 9.18% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $7.5 million (up 14.8% YoY), and the FY2025 full-year result was $7.3 million, up 19.47% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.9 million, down from $1.9 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.9 million in Q3 2025, with the low at $293000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.3 million across 5 years, with a median of $1.3 million in 2024.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) soared 259.04% — and 2026, when it increased 9.18%.
• Prime Medicine's Depreciation & Amortization (CF) stood at $870000.0 in 2022, then surged by 43.33% to $1.2 million in 2023, then jumped by 37.69% to $1.7 million in 2024, then rose by 9.26% to $1.9 million in 2025, then declined by 1.07% to $1.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.